# Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492

Nicolas Girard, Mariam Besada, Basia Rogula, Stefano Lucherini, Lien Vo, Mohammad A. Chaudhary, Sarah Goring, Greta Lozano-Ortega, Mia Tran, Nebibe Varol, et al.

► To cite this version:

Nicolas Girard, Mariam Besada, Basia Rogula, Stefano Lucherini, Lien Vo, et al.. Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. Cancers 2024, 16, 2492. Cancers, 2025, 17 (4), pp.674-674. 10.3390/cancers17040674. [https://hal.science/hal-05040070v1](https://hal.science/hal-05040070v1)

HAL Id: hal-05040070

https://hal.science/hal-05040070v1

Submitted on 22 May 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
Correction

Correction: Girard et al. Comparative Efficacy of Neoadjuvant
Nivolumab Plus Chemotherapy versus Conventional
Comparator Treatments in Resectable Non-Small-Cell Lung
Cancer: A Systematic Literature Review and Network
Meta-Analysis. *Cancers* 2024, *16*, 2492

Nicolas Girard <fnref n="1" />,<fnref n="2" />,†, Mariam Besada <fnref n="3" />,†, Basia Rogula <fnref n="3" />, Stefano Lucherini <fnref n="4" />, Lien Vo <fnref n="5" />, Mohammad A. Chaudhary <fnref n="5" />,‡,
Sarah Goring <fnref n="3" /> Ⓓ, Greta Lozano-Ortega <fnref n="3" /> Ⓓ, Mia Tran <fnref n="5" />, Nebibe Varol <fnref n="4" /> Ⓓ, Nathalie Waser <fnref n="6" /> Ⓓ, Winifred W. Yu <fnref n="6" />,‡,
Jay M. Lee <fnref n="7" /> and Jonathan Spicer <fnref n="8" />,* Ⓓ

<figure><img src="image_2.png" /></figure>

check for
updates

Received: 14 January 2025

Accepted: 15 January 2025

Published: 17 February 2025

**Citation:** Girard, N.; Besada, M.; Rogula, B.; Lucherini, S.; Vo, L.; Chaudhary, M.A.; Goring, S.; Lozano-Ortega, G.; Tran, M.; Varol, N.; et al. Correction: Girard et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. *Cancers* 2024, *16*, 2492. *Cancers* 2025, 17, 674.
https://doi.org/10.3390/cancers17040674

**Copyright:** © 2025 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license
(https://creativecommons.org/licenses/by/4.0/).

Addition of an Author

Winifred W. Yu was not included as an author in the original publication [1]. The corrected Author Contributions Statement is shown here. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

**Author Contributions:** N.G. provided clinical expertise and oversight for the study. M.B., S.G. and G.L.-O. contributed to the writing and to the design and interpretation of the analysis. B.R. performed the data analysis and contributed to the writing, design, and interpretation of the analysis. S.L., L.V. and M.A.C. contextualized the findings and contributed to the design and interpretation of the analysis. M.T., N.V., J.M.L. and J.S. provided clinical insights and contextualized the findings. N.W. and W.W.Y. conducted the systematic literature review. All authors have read and agreed to the published version of the manuscript.

<footnote n="1">¹ Department of Medical Oncology, Institut Curie, 75005 Paris, France; nicolas.girard2@curie.fr</footnote>

<footnote n="2">² Paris Saclay University, University of Versailles Saint-Quentin-en-Yvelines (UVSQ), 78000 Versailles, France</footnote>

<footnote n="3">3 Broadstreet HEOR, Vancouver, BC V6A 1A4, Canada; mbesada@broadstreetheor.com (M.B.); brogula@broadstreetheor.com (B.R.); sarah@goring.com (S.G.); glozano-ortega@broadstreetheor.com (G.L.-O.)</footnote>

<footnote n="4">4 Bristol Myers Squibb, Uxbridge UB8 1DH, UK; stefano.lucherini@bms.com (S.L.); nebibe.varol@bms.com (N.V.)</footnote>

<footnote n="5">5 Bristol Myers Squibb, Lawrenceville, NJ 08648, USA; lien.vo@bms.com (L.V.); ashraf.chaudhary@bms.com (M.A.C.); mia.tran@bms.com (M.T.)</footnote>

<footnote n="6">6 ICON Plc, Burlington, ON L7N 3G2, Canada; nathalie.waser@iconplc.com (N.W.); winifredwyu@gmail.com (W.W.Y.)</footnote>

<footnote n="7">7 UCLA Health, Los Angeles, CA 90095, USA; jaymoonlee@mednet.ucla.edu</footnote>

<footnote n="8">8 Department of Thoracic Surgery, McGill University Health Center, Montreal, QC H3G 1A4, Canada</footnote>

<footnote>* Correspondence: jonathan.spicer@mcgill.ca</footnote>

<footnote>† Co-first authors.</footnote>

<footnote>‡ At the time research was conducted.</footnote>
Reference

1. Girard, N.; Besada, M.; Rogula, B.; Lucherini, S.; Vo, L.; Chaudhary, M.A.; Goring, S.; Lozano-Ortega, G.; Tran, M.; Varol, N.; et al. Comparative Efficacy of Neoadjuvant Nivolumab Plus Chemotherapy versus Conventional Comparator Treatments in Resectable Non-Small-Cell Lung Cancer: A Systematic Literature Review and Network Meta-Analysis. *Cancers* **2024**, *16*, 2492. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.